Charles River partners with Batavia
Can now offer a seamless transition from cell line development through to cell banking, characterisation, and clinical scale manufacturing
Charles River Biopharmaceutical Services (BPS) is pleased to announce a new partnership with Batavia, allowing it to offer its clients a seamless transition from cell line development through to cell banking, characterisation, and clinical scale manufacturing of recombinant proteins, mAbs, gene therapies and virus products on a global level.
With GMP manufacturing facilities located in Leiden, Netherlands, and additional facilities in Massachusetts, Batavia provides clinical scale manufacturing of proteins, antibodies, vaccines and vectors, and assists clients with cell line development, mammalian and microbial cell culture process development and purification process development.
This partnership will help advance Charles River’s goal of making the development of drug products and vaccines as easy as possible for clients. Aided by the experience and scientific expertise of Batavia Bioservices, BPS is now able to provide clients with an even more complete solution for their early-stage drug product and vaccine development and manufacturing needs.
